Published in Hepatitis Weekly, June 12th, 1995
According to an announcement by Paracelsian President and CEO Keith Rhodes, two recent independent laboratory studies utilizing human white blood cells suggest that PN355 inhibits replication of HIV-1.
PN355 is the first member of a new class of antiviral compounds, tyrosine kinase inhibitors. In a study published in the April 24, 1992, edition of Science, Cohen et. al. from the U.S. National Institutes of Health (NIH) reported that protein-tyrosine kinase inhibitors inhibit the cytopathicity associated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.